Your browser doesn't support javascript.
loading
Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
Martín-Varillas, José Luis; Atienza-Mateo, Belén; Calvo-Rio, Vanesa; Beltrán, Emma; Sánchez-Bursón, Juan; Adán, Alfredo; Hernández-Garfella, Marisa; Valls-Pascual, Elia; Sellas-Fernández, Agustí; Ortego, Norberto; Maíz, Olga; Torre, Ignacio; Fernández-Espartero, Cruz; Jovani, Vega; Peiteado, Diana; Valle, David Díaz; Aurrecoechea, Elena; Caracuel, Miguel A; García-González, Alfredo J; Álvarez, Enrique Raya; Vegas-Revenga, Nuria; Demetrio-Pablo, Rosalía; Castañeda, Santos; González-Gay, Miguel A; Hernández, José Luis; Blanco, Ricardo.
Afiliación
  • Martín-Varillas JL; J.L. Martín-Varillas, MD, B. Atienza-Mateo, MD, V. Calvo-Rio, MD, PhD, R. Demetrio-Pablo, MD, PhD, M.A. González-Gay, MD, PhD, J.L. Hernández, MD, PhD, R. Blanco, MD, PhD, Rheumatology, Internal Medicine and Ophthalmology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, University of
  • Atienza-Mateo B; J.L. Martín-Varillas, MD, B. Atienza-Mateo, MD, V. Calvo-Rio, MD, PhD, R. Demetrio-Pablo, MD, PhD, M.A. González-Gay, MD, PhD, J.L. Hernández, MD, PhD, R. Blanco, MD, PhD, Rheumatology, Internal Medicine and Ophthalmology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, University of
  • Calvo-Rio V; J.L. Martín-Varillas, MD, B. Atienza-Mateo, MD, V. Calvo-Rio, MD, PhD, R. Demetrio-Pablo, MD, PhD, M.A. González-Gay, MD, PhD, J.L. Hernández, MD, PhD, R. Blanco, MD, PhD, Rheumatology, Internal Medicine and Ophthalmology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, University of
  • Beltrán E; E. Beltrán, MD, Rheumatology, Hospital del Mar, Barcelona.
  • Sánchez-Bursón J; J. Sánchez-Bursón, MD, PhD, Rheumatology, Hospital Universitario Virgen de Valme, Sevilla.
  • Adán A; A. Adán, MD, PhD, Rheumatology and Ophthalmology, Hospital Clinic de Barcelona, Barcelona.
  • Hernández-Garfella M; M. Hernández-Garfella, MD, Ophthalmology, Hospital General Universitario de Valencia.
  • Valls-Pascual E; E. Valls-Pascual, MD, Rheumatology, Hospital Universitario Doctor Peset, Valencia.
  • Sellas-Fernández A; A. Sellas-Fernández, MD, Rheumatology Hospital Vall d´Hebron, Barcelona.
  • Ortego N; N. Ortego, MD, PhD, E. Raya Álvarez, MD, PhD, Autoimmune Diseases, Hospital Universitario San Cecilio, Granada.
  • Maíz O; O. Maíz, MD, Rheumatology, Hospital Universitario de Donostia, San Sebastián.
  • Torre I; I. Torre, MD, Rheumatology, Hospital Universitario Basurto, Bilbao.
  • Fernández-Espartero C; C. Fernández-Espartero, MD, Rheumatology, Hospital Universitario de Móstoles, Madrid.
  • Jovani V; V. Jovani, MD, PhD, Rheumatology, Hospital General Universitario de Alicante, Alicante.
  • Peiteado D; D. Peiteado, MD, PhD, Rheumatology, Hospital Universitario La Paz.
  • Valle DD; D. Díaz Valle, MD, PhD, Ophthalmology, Hospital Clínico San Carlos, Madrid.
  • Aurrecoechea E; E. Aurrecoechea, MD, PhD, Rheumatology, Hospital Sierrallana, Torrelavega.
  • Caracuel MA; M.A. Caracuel, MD, PhD, Rheumatology, Hospital Universitario Reina Sofía, Córdoba.
  • García-González AJ; A.J. García-González, MD, Rheumatology, Hospital Universitario 12 de Octubre, Madrid.
  • Álvarez ER; N. Ortego, MD, PhD, E. Raya Álvarez, MD, PhD, Autoimmune Diseases, Hospital Universitario San Cecilio, Granada.
  • Vegas-Revenga N; N. Vegas-Revenga, MD, Rheumatology, Hospital Galdakao-Usansolo, Vizcaya.
  • Demetrio-Pablo R; J.L. Martín-Varillas, MD, B. Atienza-Mateo, MD, V. Calvo-Rio, MD, PhD, R. Demetrio-Pablo, MD, PhD, M.A. González-Gay, MD, PhD, J.L. Hernández, MD, PhD, R. Blanco, MD, PhD, Rheumatology, Internal Medicine and Ophthalmology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, University of
  • Castañeda S; S. Castañeda, MD, PhD, Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain.
  • González-Gay MA; J.L. Martín-Varillas, MD, B. Atienza-Mateo, MD, V. Calvo-Rio, MD, PhD, R. Demetrio-Pablo, MD, PhD, M.A. González-Gay, MD, PhD, J.L. Hernández, MD, PhD, R. Blanco, MD, PhD, Rheumatology, Internal Medicine and Ophthalmology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, University of
  • Hernández JL; J.L. Martín-Varillas, MD, B. Atienza-Mateo, MD, V. Calvo-Rio, MD, PhD, R. Demetrio-Pablo, MD, PhD, M.A. González-Gay, MD, PhD, J.L. Hernández, MD, PhD, R. Blanco, MD, PhD, Rheumatology, Internal Medicine and Ophthalmology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, University of
  • Blanco R; J.L. Martín-Varillas, MD, B. Atienza-Mateo, MD, V. Calvo-Rio, MD, PhD, R. Demetrio-Pablo, MD, PhD, M.A. González-Gay, MD, PhD, J.L. Hernández, MD, PhD, R. Blanco, MD, PhD, Rheumatology, Internal Medicine and Ophthalmology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, University of
J Rheumatol ; 48(5): 741-750, 2021 05.
Article en En | MEDLINE | ID: mdl-33004539
OBJECTIVE: In a large series of White patients with refractory uveitis due to Behçet disease (BD) being treated with infliximab (IFX), we assessed (1) long-term efficacy and safety of IFX, and (2) IFX optimization when ocular remission was achieved. METHODS: Our multicenter study of IFX-treated patients with BD uveitis refractory to conventional immunosuppressant agents treated 103 patients/185 affected eyes with IFX as first biologic therapy in the following intervals: 3-5 mg/kg intravenous at 0, 2, 6, and then every 4-8 weeks. The main outcome variables were analyzed at baseline, first week, first month, sixth month, first year, and second year of IFX therapy. After remission, based on a shared decision between patient and clinician, IFX optimization was performed. Efficacy, safety, and cost of IFX therapy were evaluated. RESULTS: In the whole series (n = 103), main outcome variables showed a rapid and maintained improvement, reaching remission in 78 patients after a mean IFX duration of 31.5 months. Serious adverse events were observed in 9 patients: infusion reactions (n = 4), tuberculosis (n = 1), Mycobacterium avium pneumonia (n = 1), severe oral ulcers (n = 1), palmoplantar psoriasis (n = 1), and colon carcinoma (n = 1). In the optimization subanalysis, the comparative study between optimized and nonoptimized groups showed (1) no differences in clinical characteristics at baseline, (2) similar maintained improvement in most ocular outcomes, (3) lower severe adverse events, and (4) lower mean IFX costs in the optimized group (€4826.52 vs €9854.13 per patient/yr). CONCLUSION: IFX seems to be effective and relatively safe in White patients with refractory BD uveitis. IFX optimization is effective, safe, and cost-effective.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis / Síndrome de Behçet Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Rheumatol Año: 2021 Tipo del documento: Article Pais de publicación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis / Síndrome de Behçet Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Rheumatol Año: 2021 Tipo del documento: Article Pais de publicación: Canadá